Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAGI3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAGI3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAGI3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MAGI3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MAGI3_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAGI3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAGI3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAGI3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAGI3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAGI3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAGI3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00072542 | Stomach | CAG with IM | JNK cascade | 18/1050 | 167/18723 | 5.96e-03 | 4.62e-02 | 18 |
GO:000915021 | Stomach | CSG | purine ribonucleotide metabolic process | 46/1034 | 368/18723 | 1.89e-07 | 1.26e-05 | 46 |
GO:000616321 | Stomach | CSG | purine nucleotide metabolic process | 48/1034 | 396/18723 | 2.61e-07 | 1.66e-05 | 48 |
GO:000925921 | Stomach | CSG | ribonucleotide metabolic process | 46/1034 | 385/18723 | 6.97e-07 | 3.75e-05 | 46 |
GO:007252121 | Stomach | CSG | purine-containing compound metabolic process | 48/1034 | 416/18723 | 1.11e-06 | 5.64e-05 | 48 |
GO:001969321 | Stomach | CSG | ribose phosphate metabolic process | 46/1034 | 396/18723 | 1.54e-06 | 7.39e-05 | 46 |
GO:000911721 | Stomach | CSG | nucleotide metabolic process | 52/1034 | 489/18723 | 4.59e-06 | 1.84e-04 | 52 |
GO:000675321 | Stomach | CSG | nucleoside phosphate metabolic process | 52/1034 | 497/18723 | 7.29e-06 | 2.62e-04 | 52 |
GO:003287221 | Stomach | CSG | regulation of stress-activated MAPK cascade | 25/1034 | 192/18723 | 5.87e-05 | 1.47e-03 | 25 |
GO:007030221 | Stomach | CSG | regulation of stress-activated protein kinase signaling cascade | 25/1034 | 195/18723 | 7.59e-05 | 1.82e-03 | 25 |
GO:003109821 | Stomach | CSG | stress-activated protein kinase signaling cascade | 29/1034 | 247/18723 | 1.05e-04 | 2.29e-03 | 29 |
GO:005140321 | Stomach | CSG | stress-activated MAPK cascade | 28/1034 | 239/18723 | 1.43e-04 | 2.97e-03 | 28 |
GO:000913221 | Stomach | CSG | nucleoside diphosphate metabolic process | 18/1034 | 124/18723 | 1.57e-04 | 3.17e-03 | 18 |
GO:000913521 | Stomach | CSG | purine nucleoside diphosphate metabolic process | 16/1034 | 103/18723 | 1.61e-04 | 3.20e-03 | 16 |
GO:000917921 | Stomach | CSG | purine ribonucleoside diphosphate metabolic process | 16/1034 | 103/18723 | 1.61e-04 | 3.20e-03 | 16 |
GO:000918521 | Stomach | CSG | ribonucleoside diphosphate metabolic process | 16/1034 | 106/18723 | 2.26e-04 | 4.26e-03 | 16 |
GO:00467102 | Stomach | CSG | GDP metabolic process | 4/1034 | 11/18723 | 2.23e-03 | 2.25e-02 | 4 |
GO:004632811 | Stomach | CSG | regulation of JNK cascade | 16/1034 | 133/18723 | 2.74e-03 | 2.62e-02 | 16 |
GO:000725411 | Stomach | CSG | JNK cascade | 18/1034 | 167/18723 | 5.10e-03 | 4.17e-02 | 18 |
GO:001969327 | Thyroid | PTC | ribose phosphate metabolic process | 176/5968 | 396/18723 | 8.28e-08 | 1.70e-06 | 176 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGI3 | SNV | Missense_Mutation | novel | c.77N>T | p.Pro26Leu | p.P26L | Q5TCQ9 | protein_coding | tolerated(0.34) | benign(0.088) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
MAGI3 | SNV | Missense_Mutation | | c.2056N>A | p.Gln686Lys | p.Q686K | Q5TCQ9 | protein_coding | deleterious(0.04) | possibly_damaging(0.493) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
MAGI3 | SNV | Missense_Mutation | novel | c.1031G>T | p.Gly344Val | p.G344V | Q5TCQ9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
MAGI3 | SNV | Missense_Mutation | | c.3715N>C | p.Ile1239Leu | p.I1239L | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.65) | benign(0.001) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
MAGI3 | SNV | Missense_Mutation | | c.3508N>C | p.Lys1170Gln | p.K1170Q | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.59) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGI3 | SNV | Missense_Mutation | rs573108619 | c.3941G>A | p.Arg1314Gln | p.R1314Q | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.3) | benign(0.001) | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAGI3 | SNV | Missense_Mutation | novel | c.655N>G | p.Gln219Glu | p.Q219E | Q5TCQ9 | protein_coding | deleterious(0.03) | possibly_damaging(0.845) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
MAGI3 | SNV | Missense_Mutation | novel | c.1433A>C | p.Gln478Pro | p.Q478P | Q5TCQ9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MAGI3 | SNV | Missense_Mutation | novel | c.3782G>T | p.Gly1261Val | p.G1261V | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.22) | benign(0.003) | TCGA-E2-A573-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAGI3 | SNV | Missense_Mutation | novel | c.3708N>T | p.Leu1236Phe | p.L1236F | Q5TCQ9 | protein_coding | tolerated_low_confidence(0.44) | benign(0.157) | TCGA-E9-A22D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |